 Home > Medical News > Medicines Company News > ATG-019 clinical trial application for the treatment of advanced solid tumors and non-Hodgkin's lymphoma was approved in China

ATG-019 clinical trial application for the treatment of advanced solid tumors and non-Hodgkin's lymphoma was approved in China

 Last Update: 2021-05-03
 Source: Internet
 Author: User

Tags

food safety organizations

ake safety equipment

consumer safety

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Deck Pharmaceuticals announced today that the State Food and Drug Administration has approved the application of ATG-019 to start a phase I clinical trial, which aims to evaluate ATG-019 (single agent or combined with niacinER) in advanced solid tumors or non-Hodgkin’s lymphoma in China Safety and tolerability in patients.

As a PAK4/NAMPT dual-target inhibitor with oral bioavailability, ATG-019 exerts anti-tumor effects through energy consumption, DNA repair inhibition, cell cycle arrest and cell proliferation inhibition, and ultimately promotes cell apoptosis.

Deqi Pharmaceuticals has launched a phase I clinical trial (TEACH) of ATG-019 for the treatment of advanced solid tumors and non-Hodgkin's lymphoma in Taiwan, China.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.